JP2009529041A5 - - Google Patents

Download PDF

Info

Publication number
JP2009529041A5
JP2009529041A5 JP2008558230A JP2008558230A JP2009529041A5 JP 2009529041 A5 JP2009529041 A5 JP 2009529041A5 JP 2008558230 A JP2008558230 A JP 2008558230A JP 2008558230 A JP2008558230 A JP 2008558230A JP 2009529041 A5 JP2009529041 A5 JP 2009529041A5
Authority
JP
Japan
Prior art keywords
carboxamide
pyridin
amino
methylpiperazin
pyrazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008558230A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009529041A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SE2007/000216 external-priority patent/WO2007102770A1/en
Publication of JP2009529041A publication Critical patent/JP2009529041A/ja
Publication of JP2009529041A5 publication Critical patent/JP2009529041A5/ja
Pending legal-status Critical Current

Links

JP2008558230A 2006-03-08 2007-03-06 骨粗鬆症治療のためのgsk−3阻害薬 Pending JP2009529041A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78025206P 2006-03-08 2006-03-08
PCT/SE2007/000216 WO2007102770A1 (en) 2006-03-08 2007-03-06 Gsk-3 inhibitors for the treatment of osteoporosis

Publications (2)

Publication Number Publication Date
JP2009529041A JP2009529041A (ja) 2009-08-13
JP2009529041A5 true JP2009529041A5 (enExample) 2010-04-22

Family

ID=38475142

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008558230A Pending JP2009529041A (ja) 2006-03-08 2007-03-06 骨粗鬆症治療のためのgsk−3阻害薬

Country Status (16)

Country Link
US (1) US7576093B2 (enExample)
EP (1) EP1993550A4 (enExample)
JP (1) JP2009529041A (enExample)
KR (1) KR20080114717A (enExample)
CN (1) CN101394851A (enExample)
AR (1) AR059754A1 (enExample)
AU (1) AU2007222199A1 (enExample)
BR (1) BRPI0708619A2 (enExample)
CA (1) CA2644751A1 (enExample)
IL (1) IL193484A0 (enExample)
MX (1) MX2008011417A (enExample)
NO (1) NO20084182L (enExample)
TW (1) TW200800203A (enExample)
UY (1) UY30192A1 (enExample)
WO (1) WO2007102770A1 (enExample)
ZA (1) ZA200807234B (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100137330A1 (en) * 2007-03-08 2010-06-03 Ratan Bhat Use
JP5702293B2 (ja) 2008-11-10 2015-04-15 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Atrキナーゼの阻害剤として有用な化合物
BRPI0924084B1 (pt) 2008-12-19 2021-12-21 Vertex Pharmaceuticals Incorporated Derivados de pirazina e composição farmacêutica que os compreende
US8198285B2 (en) * 2010-01-19 2012-06-12 Astrazeneca Ab Pyrazine derivatives
JP2013526538A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼ阻害剤として有用な化合物
WO2011143422A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated 2 -aminopyridine derivatives useful as inhibitors of atr kinase
US9062008B2 (en) 2010-05-12 2015-06-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8962631B2 (en) 2010-05-12 2015-02-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
AU2011253025A1 (en) 2010-05-12 2012-11-29 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2569287B1 (en) 2010-05-12 2014-07-09 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
WO2011163527A1 (en) 2010-06-23 2011-12-29 Vertex Pharmaceuticals Incorporated Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase
WO2012138938A1 (en) 2011-04-05 2012-10-11 Vertex Pharmaceuticals Incorporated Aminopyrazine compounds useful as inhibitors of tra kinase
CA2832605C (en) * 2011-05-23 2016-03-29 Merck Patent Gmbh Pyridine-and pyrazine derivatives
JP2014522818A (ja) 2011-06-22 2014-09-08 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼ阻害剤として有用な化合物
EP2723745A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
JP2014517079A (ja) 2011-06-22 2014-07-17 バーテックス ファーマシューティカルズ インコーポレイテッド Atrキナーゼ阻害剤として有用な化合物
MX2014003796A (es) 2011-09-30 2015-01-16 Vertex Pharma Compuestos utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr).
IN2014CN02501A (enExample) 2011-09-30 2015-06-26 Vertex Pharma
WO2013049719A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
SG10201606774UA (en) 2011-09-30 2016-10-28 Vertex Pharma Processes for making compounds useful as inhibitors of atr kinase
WO2013049720A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2776421A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2776422A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8841449B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2013071093A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
EP2776429A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US20140044802A1 (en) 2012-04-05 2014-02-13 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase and combination therapies thereof
DK2904406T3 (en) 2012-10-04 2018-06-18 Vertex Pharma METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
US8912198B2 (en) 2012-10-16 2014-12-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
SMT202000713T1 (it) 2012-12-07 2021-03-15 Vertex Pharma Pirazolo [1,5-a] pirimidine utili come inibitori dell'atr chinasi per il trattamento di malattie del cancro
DK2970890T3 (da) 2013-03-14 2020-05-04 Brigham & Womens Hospital Inc Sammensætninger og fremgangsmåder til opformering og dyrkning af epitelstamceller
JP2016512815A (ja) 2013-03-15 2016-05-09 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Atrキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
HUE046727T2 (hu) 2013-12-06 2020-03-30 Vertex Pharma Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai
CN103804312B (zh) * 2014-02-17 2016-04-20 四川百利药业有限责任公司 一类氮杂环化合物及其制备方法和用途
CN107074863B (zh) 2014-06-05 2019-12-03 沃泰克斯药物股份有限公司 Atr激酶抑制剂的制备方法及其不同的固体形式
PL3157566T3 (pl) 2014-06-17 2019-10-31 Vertex Pharma Metoda leczenia nowotworu przy użyciu kombinacji inhibitorów chk1 i atr
WO2016037016A1 (en) 2014-09-03 2016-03-10 The Brigham And Women's Hospital, Inc. Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
KR102678021B1 (ko) 2015-09-30 2024-06-26 버텍스 파마슈티칼스 인코포레이티드 Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물
JP2019506153A (ja) 2016-01-08 2019-03-07 マサチューセッツ インスティテュート オブ テクノロジー 分化した腸内分泌細胞およびインスリン産生細胞の作製
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
MX390321B (es) 2016-12-30 2025-03-20 Frequency Therapeutics Inc Compuestos de 1h-pirrol-2,5-diona y metodos de uso de los mismos para inducir la auto-renovacion de celulas madre/progenitoras de soporte.
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
JP2021533788A (ja) 2018-08-17 2021-12-09 フリークエンシー セラピューティクス インコーポレイテッド Jag−1を上方制御することにより有毛細胞を生成するための組成物及び方法
EP3920885A1 (en) 2019-02-08 2021-12-15 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
KR20260049706A (ko) * 2023-07-14 2026-04-14 재즈 파마슈티컬스 테라퓨틱스, 인크. Atr 억제제를 포함하는 리포좀 조성물의 사용 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL145757A (en) 2000-02-05 2007-12-03 Vertex Pharma History of pyrazole and pharmaceutical preparations containing them
SE0102438D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0102439D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
AU2003235798A1 (en) * 2002-01-10 2003-07-24 F. Hoffmann-La Roche Ag Use of a gsk-3beta inhibitor in the manufacture of a medicament for increasing bone formation
CA2477967C (en) 2002-03-05 2010-08-10 Eli Lilly And Company Purine derivatives as kinase inhibitors
SE0203752D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
EP1636388A2 (en) 2003-06-06 2006-03-22 Wyeth Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby
JP2007502300A (ja) 2003-08-13 2007-02-08 カイロン コーポレイション Gsk−3インヒビターおよびその使用
US20050064044A1 (en) * 2003-09-19 2005-03-24 Georges Rawadi GSK-3beta inhibitors in the treatment of bone-related diseases

Similar Documents

Publication Publication Date Title
NO20084182L (no) GSK-3 inhibitorer for behandling av osteoporose
RU2012132692A (ru) Новые ингибиторы s-нитрозоглутатионредуктазы
RU2005135016A (ru) Производные хинолина в качестве ингибиторов фосфодиэстеразы
GB0324654D0 (en) Medicinal compounds
JP2016512825A5 (enExample)
JP2010509242A5 (enExample)
JP2006504656A5 (enExample)
JP2013500986A5 (enExample)
EA200200551A1 (ru) Новые содержащие тиотропий порошки для ингаляции
JP2007502806A5 (enExample)
HRP20050432A2 (en) Novel medicaments for the treatment of chronic obstructive pulmonary diseases
RU2003114752A (ru) Лечение желудочно-кишечных стромальных опухолей
JP2004512328A5 (enExample)
DE602005026007D1 (de) Opioide zur behandlung von chronisch-obstruktiver lungenerkrankung (copd)
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
JP2004504400A5 (enExample)
RU2003133924A (ru) Дейтерированные 3-пиперидиноэтилфенилкетоны, а также лекарственные средства, содержащие эти соединения
JP2010521516A5 (enExample)
MXPA03011702A (es) Composicion que comprende un inhibidor de fosodiesterasa 4 y un antagonista de receptor h1 y el uso de los mismos para la elaboracion de un medicamento para el tratamiento de enfermedades respiratorias.
JP2010504321A5 (enExample)
EA200600854A1 (ru) Новые соли тиотропия, способ их получения, а также содержащие их лекарственные композиции
WO2005011594A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease
EA200600886A1 (ru) Способ получения солей тиотропия, соли тиотропия, а также содержащие их лекарственные композиции
JP2010526051A5 (enExample)
DE50312523D1 (de) Pharmazeutische wirkstoffkombination sowie deren verwendung